Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
PolyNovo (ASX:PNV) is a medical device company whose wound care technology has drawn growing interest from small-cap managers as its valuation has fallen. In May 2026, Endeavor Asset Management reported the shares rose 22% after PolyNovo finalised a US clinical study supporting its FDA premarket approval update, allowing 18-month follow-up data to be included in the submission. Earlier in 2026, Endeavor noted a healthcare sell-off had pushed PolyNovo to its lowest valuation multiples on record. PolyNovo operates in the Healthcare sector within the Healthcare Equipment and Supplies industry, and Thesis Tracker has captured 14 comments from 4 fund managers, including Endeavor Asset Management and Forager Funds. Headquartered in Melbourne, PolyNovo develops medical devices based on its patented NovoSorb biodegradable polymer, with its Biodegradable Temporizing Matrix used to treat severe burns and complex wounds.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Endeavor Asset Management, Blackwattle Investment Partners, Selector Funds Management and Forager Funds have invested in Polynovo Ltd (ASX:PNV).
Endeavor highlights progress toward an expanded FDA premarket approval, supported by longer-term clinical data, and a valuation of around 3.5 times forward EV to sales after the sell-off, the lowest it has seen. NovoSorb's versatility across wound types supports continued adoption.
Endeavor noted the shares fell when healthcare sentiment weakened and the policy backdrop turned cautious, and Forager Funds observed competing products such as Aroa's may be preferred for necrotised wounds. Regulatory timing for the FDA approval remains a key risk.
Polynovo Ltd. is an Australian-headquartered medical device company specializing in patented NovoSorb biodegradable polymer technology. Its core product is the Biodegradable Temporizing Matrix (BTM), designed for advanced wound care. Founded in 1998, the company operates internationally across three primary geographical segments: the United States, Australia and New Zealand, and other global markets. Polynovo focuses on the research, development, and commercialization of medical solutions for therapeutic applications.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.